Table 3.
Primary results, tier 1
| Studies (N) | Cancers (N) | Ref. groupa (N) | OR | 95% CI | p value | |
|---|---|---|---|---|---|---|
| Tier 1 | ||||||
| Overall | 9 | 4916 | 2497 | 4.4 | (2.0, 9.5) | 2.3 × 10–4 |
| Subtypes | ||||||
| Family history | ||||||
| FH + cancers vs noncancers | 7 | 1708 | 2283 | 5.6 | (2.3, 13.9) | 2.0 × 10–4 |
| FH– cancers vs noncancers | 6 | 2289 | 2207 | 3.3 | (1.4, 7.9) | 0.008 |
| FH + vs FH– cancers | 8 | 1955 | 2543 | 1.3 | (0.8, 2.3) | 0.305 |
| Metastatic | ||||||
| M1 cancers vs noncancers | 4 | 378 | 2074 | 6.4 | (2.0, 20.6) | 0.002 |
| M0 cancers vs noncancers | 8 | 3491 | 2410 | 3.8 | (1.7, 8.5) | 0.001 |
| M1 vs M0 cancers | 9 | 504 | 3910 | 1.8 | (0.8, 4.0) | 0.146 |
| Gleason | ||||||
| Gleason ≥8 vs noncancers | 6 | 1153 | 2207 | 5.5 | (2.2, 13.8) | 2.3 × 10–4 |
| Gleason 7 vs noncancers | 7 | 1064 | 2316 | 3.9 | (1.5, 10.4) | 0.006 |
| Gleason ≤6 vs noncancers | 5 | 1743 | 2113 | 3.1 | (1.2, 8.1) | 0.018 |
| Gleason ≥8 vs Gleason ≤6 | 7 | 1220 | 1952 | 1.3 | (0.7, 2.5) | 0.431 |
| Aggressive | ||||||
| Agg. vs noncancers | 8 | 2108 | 2410 | 5.4 | (2.4, 12.5) | 7.4 × 10–5 |
| Non-Agg. vs noncancers | 5 | 1412 | 2113 | 3.2 | (1.1, 9.2) | 0.028 |
| Agg. vs non-Agg. Cancers | 9 | 2184 | 1613 | 1.6 | (0.9, 3.0) | 0.135 |
| Age at diagnosis | ||||||
| <65 cancers vs noncancers | 8 | 3095 | 2410 | 4.9 | (2.2, 11.1) | 1.3 × 10–4 |
| ≥65 cancers vs noncancers | 8 | 1652 | 2421 | 3.8 | (1.4, 10.4) | 0.010 |
| <65 cancers vs ≥65 cancers | 10 | 3623 | 1650 | 2.0 | (1.0, 3.7) | 0.037 |
Agg. = aggressive; CI = confidence interval; FH = family history; OR = odds ratio; Ref. = reference.
a
Controls for case/control analyses. Lower-risk subcategory for case-only analyses.